-0.05(-0.36%)

0.0000(-0.0000%)

Nine Studies of GeoMx DSP for High-Plex Spatial RNA Profiling and Three Studies of Hyb & Seq for Clinical Applications

SEATTLE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a wave of studies demonstrating the power and potential of its two major pipeline products. Both the GeoMx™ Digital Spatial Profiler (DSP) and the novel Hyb & Seq™ sequencing chemistry leverage NanoString’s optical barcoding technology to address new market opportunities in biologic research and diagnostics. These technologies will be showcased in a total of twelve scientific studies (three oral presentations and nine posters), at the Advances in Genome Biology and Technology (AGBT) conference being held at the JW Marriott in Marco Island, Florida.

“We are delighted that our emerging products are garnering so much visibility at AGBT, the bellwether conference for showcasing biological research tools and emerging applications,” said Brad Gray, president and CEO of NanoString. “We are particularly excited that our GeoMx DSP system will be so strongly featured. The NanoString team, our Technology Access Program participants, and our beta sites are presenting a total of nine studies highlighting spatial RNA and protein profiling of more than 250 tumor biopsy sections from seven different cancer types.”

GeoMx Digital Spatial Profiling

GeoMx DSP enables high throughput multiplex spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The full launch of the GeoMx DSP platform is scheduled to take place at the upcoming meeting of the American Association of Cancer Research (AACR) being held March 29-April 3, 2019, and over 30 systems have already been pre-ordered. At AGBT 2019, studies performed by six leading academic researchers demonstrate three major achievements for GeoMx DSP:

High-Plex RNA profiling with NGS readout: Three independent studies led by leading academic researchers demonstrate GeoMx DSP’s ultra-high-plex RNA chemistry read out using next generation sequencing. Each experiment spatially profiled 1,400+ mRNAs, illustrating the platform’s high precision and opportunity to map biological pathways in space.

First Results from Spatial Genomics Center of Excellence: Researchers from the Broad Institute will share high-plex spatial RNA and protein analysis generated using a beta instrument run on-site covering six different tissue types.

NanoString’s proprietary Hyb & Seq chemistry is designed to enable a workflow that is simpler and faster than current sequencing methods due to the absence of library preparation, enzymes and amplification. Hyb & Seq’s simple workflow, compatibility with a variety of sample types, and ability to sequence both DNA and RNA in parallel offer the potential for an ideal sample-to-answer solution for clinical sequencing. The Hyb & Seq platform is expected to be commercially launched in 2021. At AGBT 2019, studies performed in collaboration with two leading academic researchers demonstrate ongoing progress in technology development:

First Data from Fully-Scaled Sequencing Chemistry: Researchers from the University of Cambridge will present the first sample-to-answer workflow using all 4,096 Hyb & Seq barcodes, sequencing the entire coding region of the TP53 gene.

A detailed list of presentations and posters covering the GeoMx DSP and Hyb & Seq technology is provided below. The GeoMx DSP and Hyb & Seq technology are currently for research use only and are not for use in diagnostic procedures.

Demonstrates high level of technical and biological reproducibility of the high-plex RNA chemistry with next generation sequencing readout. Moreover the study focused on identifying biomarkers that predict the likelihood of progression from dysplastic nevi to advance stages of melanoma.

This study highlights the importance of high-plex spatial profiling to subtype prostate cancers at a resolution that cannot be readily achieved using traditional IHC technology or RNAseq. Using spatial profiling of RNA and protein, unique marker populations associated with typical adenocarcinoma phenotype vs neuroendocrine phenotype can be identified.

This study highlights the resolution of the platform to select, illuminate and spatially profile proteins at single cell scale. This proof of concept experiment demonstrates resolution capability that enables cell phenotyping applications.

This study demonstrates the performance of the high plex spatial RNA chemistry. A 1412 spatial RNA plex panel compatible with next generation sequencing readout was designed to capture tumor and immune biology. The high plex RNA probes were tested across 23 well characterized fixed cell lines as well as FFPE tissue sections to ensure specificity and precision of the assay.

High plex spatial RNA profiling of colecteral cancer samples showed differential activation of signaling pathways was influenced by microsatellite instable (MSI) or microsatellite stable (MSS) status but also regional differences within the tissue. Moreover, this study highlights the ability of the high plex spatial RNA chesmitry to profile lowly abundant targets like chemokines.

About NanoString Technologies, Inc.NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 3,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.